After massive gains in the past five years on the heels of the weight loss blockbuster Zepbound, Eli Lilly & Co (LLY) stock ...

Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...

Can a weight-loss drug become a weapon of war? Once, that question might have seemed absurd. No longer. Earlier this year, when US President Donald Trump offered to buy Greenland from Denmark ...

Advances recognized by science’s most lucrative awards include Large Hadron Collider experiments and groundbreaking ...

People taking a popular diabetes medication called semaglutide, sold under brand names like Ozempic, Wegovy, and Rybelsus may ...

Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an “important” weight loss treatment.

Denmark’s benchmark stock index has fallen 21% from its September high, making it the first major European index to enter a bear market as tariff-related risks and a slump for Novo Nordisk A/S weigh.

Antag Therapeutics initiates Phase 1a trial of AT-7687, a first-in-class GIPR antagonist designed to address key gaps in obesity treatment First ...

A Canadian researcher has won a 2025 Breakthrough Prize in Life Sciences for discovering the GLP-1 hormone used in diabetes and obesity medications — including Ozempic, Wegovy and Mounjaro ...

Packets of Wegovy move along the line at the Novo Nordisk A/S production facilities in Hillerod, Denmark, on March 8, 2024. Packets of Wegovy move along the line at the Novo Nordisk A/S production ...

My name is Alex and I eat food for a living. I love what I do but I feel horrible about how I look so I decided to change that. My trainer @bodybyvenus has taken on the task of turning a foodie ...